Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Haleon selling ChapStick to Suave Brands to pay down debt

Haleon selling ChapStick to Suave Brands to pay down debt

The sale is expected to close in the second quarter of 2024, the company said. 

Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands Company, a company owned by American private equity firm Yellow Wood Partners.


The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer, valued at around $80 million.

Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt.

ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024.

Brian McNamara, Chief Executive Officer, Haleon, said: “Today’s announcement is consistent with Haleon being proactive in managing our portfolio, and being rigorous and disciplined where there are opportunities for divestment.

“While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.

“Selling the brand allows us to simplify our business and pay down debt more quickly. We’re confident the brand will continue to thrive under its new ownership.”

The company said it would be providing further detail on the transaction and its impact within its FY 2023 results announcement on 29 February 2024.

Haleon’s product portfolio spans five major categories - oral health, pain relief, respiratory health, digestive health and other, and vitamins, minerals and supplements (vms) – and its other brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum.

Last week, it was reported that Haleon was in talks with Indian pharmaceutical group Dr. Reddy's Laboratories to sell Nicotinell, the anti-smoking aid, but the transaction was likely to be below the $800 million asking price suggested earlier.

In July, Haleon completed the sale of Lamisil, an antifungal treatment, to Karo Healthcare for £235 million.

More For You

Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less
Pharma industry group unhappy with NHS drug pricing offer

The ABPI warned that £2 billion of potential investment could be under risk

Pic credit: istock

Pharma industry group unhappy with NHS drug pricing offer

The Association of the British Pharmaceutical Industry (ABPI) has rejected the UK government’s offer to cut the cost of NHS drugs pricing scheme as it felt it was inadequate.

The industry group warned that £2 billion of potential investment could be under risk and wanted prime minister Keir Starmer to intervene, The Times reports.

Keep ReadingShow less
Day Lewis celebrates 50 years of delivering care to communities

The Patel family at the unveiling of the commemorative plaque ceremony

Day Lewis celebrates 50 years of delivering care to communities

Day Lewis honoured "the people, purpose and partnerships" as it celebrated 50 years of service by unveiling a commemorative plaque at the company’s support office in Croydon.

As one of the UK’s largest independent pharmacy chains, Day Lewis has delivered trusted care to communities across the country since it was founded in 1975, by brothers Kirit and JC Patel, who was on hand to unveil the plaque.

Keep ReadingShow less
CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

Pic credit: iStock

Pharmacy owners asked to share views on new contract and its financial implications

Pharmacy owners can share their thoughts on service developments and their financial security before the upcoming Community Pharmacy England (CPE) committee meeting to be held on June 25 and 26.

The new Community Pharmacy Contractual Framework (CPCF) was completed in March with the various service and regulatory changes still in progress.

Keep ReadingShow less
Cancer treatment impact

There have been supply issues with Creon since the summer of 2024

Pic credit: iStock

Cancer patients struggle amid digestive drug shortage

Pharmacists in the Channel Islands have revealed that there is a shortage of a drug used to support digestion in cancer patients.

Creon is a pancreatic enzyme replacement therapy (PERT), which helps people living with conditions such as cystic fibrosis, pancreatitis, and pancreatic cancer to digest food.

Keep ReadingShow less